Xigris licence withdrawn

Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY
Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY

Xigris (activated drotrecogin alfa) has been withdrawn by Lilly after it failed to show a survival benefit in a clinical trial in patients with septic shock.

Results from the PROWESS-SHOCK study showed the overall 28-day mortality was 26.4% in drotrecogin-alfa-treated patients (n=846) compared with 24.2% in patients given placebo (n=834; p=0.31). No new safety findings were observed.

Drotrecogin alfa must not be initiated in new patients and should be discontinued in patients currently receiving treatment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Migraine treatments and prophylactics summarised in new MIMS table

Migraine treatments and prophylactics summarised in new MIMS table

The latest quick reference table to be added to MIMS...

New research supports statin prescribing in patients over 75 years

New research supports statin prescribing in patients over 75 years

Evidence suggesting a mortality benefit of statins...